Iceland· IS-EU/1/23/1738/004-009
Jaypirca
A pirtobrutinib product containing pirtobrutinib, registered in Iceland by Eli Lilly Nederland B.V.*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Pirtobrutinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EL05 (pirtobrutinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Pirtobrutinib · ATC L01EL05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pirtobrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.20 in France to $369.10 in Switzerland — a ×1801 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pirtobrutinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$369.10
- FR France$0.20
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Pirtobrutinib
- Manufacturer
- Eli Lilly Nederland B.V.*
- Country
- Iceland (IS)
- ATC code
- L01EL05
- ATC class
- Pirtobrutinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean97470456 stk x1 pakkiISK 1952657
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pirtobrutinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJAYPIRCAEli Lilly Nederland B.V., Utrecht
- SwitzerlandJaypirca
- FinlandJaypircaEli Lilly Nederland B.V
- FranceJAYPIRCA 100 mg, comprimé pelliculéELI LILLY NEDERLAND BV (PAY-BAS)
- IrelandJaypirca 100 mg film-coated tabletsEli Lilly Nederland B.V.
- NetherlandsJaypirca 100 mg filmomhulde tablettenEli Lilly Nederland B.V.
- NorwayJaypircaEli Lilly Nederland B.V.
- PolandJaypircaEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Jaypirca
- Norway · Jaypirca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4e0835c6-ee03-40e3-8395-d19b6137ee8d GET /v1/drugs/4e0835c6-ee03-40e3-8395-d19b6137ee8d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EL05",
"marketed": false,
"strength": "100 mg",
"ma_number": "EU/1/23/1738/004-009",
"substance": "Pirtobrutinib",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum og krabbameinslækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "45229"
}See everything about pirtobrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.